Q3 FY2025 · ended Sep 30, 2025 · Revenue $2,000, -77.8% YoY · Filed Nov 13, 2025
Nexentis Technologies Inc. (NXTS) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$540,000. As of Jun 30, 2026 it held $8.9 million in cash and investments and $219,000 in total debt.
Revenue
$2,000
-77.8% vs year-ago quarter
Net income
$-11.14M
-147.2% vs year-ago quarter
Operating cash flow
$-539,000
-2.1% vs year-ago quarter
Free cash flow
$-540,000
+63.8% vs prior quarter
EPS
$-13.66
+69.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
1.45M
-95.6% vs year-ago quarter
Net cash
$8.66M
Q2 FY2026
Operating margin
-2391.4%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NXTS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1789192
- Former names
- N2OFF, Inc. (until Feb 25, 2026); Save Foods, Inc. (until Mar 19, 2024); Save Foods Inc. (until Apr 10, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $2,000 | $0 |
| Operating income | -$1.9M | -$8.2M | $549,000 | -$1.3M | -$2.6M |
| Net income | -$11.1M | -$6.6M | $1.3M | $429,000 | -$4.5M |
| Diluted EPS | -$13.66 | -$10.74 | $0.46 | $0.97 | -$44.26 |
| Operating cash flow | -$539,000 | -$1.4M | -$1.5M | -$974,000 | -$528,000 |
| Free cash flow | -$540,000 | -$1.5M | — | — | — |
| Total assets | $18.7M | $16.4M | $20.4M | $11.0M | $7.8M |
| Total liabilities | $16.9M | $3.5M | $4.7M | $2.4M | $2.2M |
| Stockholders' equity | $1.9M | $13.0M | $16.0M | $8.9M | $5.8M |
| Cash and investments | $8.9M | $6.2M | $4.1M | $6.3M | $3.4M |
| Total debt | $219,000 | $370,000 | $755,000 | $1.1M | $13,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Unregistered share sale, Officer or director change
|
Oct 19, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Material agreement
|
Oct 6, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Listing notice
|
Sep 3, 2026 | Aug 31, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Auditor change
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jun 22, 2026 | Jun 22, 2026 |
All 309 Nexentis Technologies Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.